The role of Survivin as a biomarker and potential prognostic factor for breast cancer

• Autor(a) principal: Veiga,Glaucia Luciano da
• Data de Publicação: 2019
• Outros Autores: Silva,Raissa Daniel Machado da, Pereira,Edimar Cristiano, Azzalis,Ligia Ajaime, Alves,Beatriz da Costa Aguiar, Gehrke,Flavia de Sousa, Gascón,Thaís Moura, Fonseca,Fernando Luiz Affonso
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Revista da Associação Médica Brasileira (Online)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0104-42302019000600893
• topic: Breast Neoplasms; Prognosis; Neoplasm Metastasis; Inhibitor of Apoptosis Proteins

SUMMARY Breast cancer (BC) is one of the primary health problems worldwide. As the most common cancer in women in the world and in Brasil, behind only non-melanoma skin cancer, this neoplasm corresponds to approximately 28% of new cases per year in the country. BC also affects men, although the incidence corresponds to only 1% of total cases. Currently, most of the chemotherapeutic agents used in BC treatment are extremely toxic and cause long-term side effects. There is also a need to obtain earlier diagnoses, more accurate prognoses and make new therapies available that are more selective and effective in order to improve the current scenario. Therefore, this work sought to evaluate the importance of the biomarker survivin (Sur) in relation to BC, through the detailing of the role of Sur as a biomarker, the correlation between this protein and the prognosis of BC patients, and a summary of therapeutic strategies that target Sur for the development of new anticancer therapies.